Engflag

Donnatal Elixir

Quick links to important sections

Donnatal Elixir

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Donnatal Elixir

Property Description
Active Ingredients Phenobarbital, Hyoscyamine, Atropine, Scopolamine
Form Elixir (Pharmaceutical Solution)
Pharmacological Class Anticholinergic/Antispasmodic Agent, Barbiturate Sedative
General Purpose Provides symptomatic relief for gastrointestinal distress
Origin Combination of Natural Alkaloids and a Synthetic Compound

Donnatal Elixir is a combination medication and a human prescription drug that is classified as both an antispasmodic agent and a barbiturate sedative. This liquid preparation is formulated as an elixir, a type of pharmaceutical solution intended for oral administration. The medication is used as adjunctive therapy for functional gastrointestinal symptoms, offering a dual-action approach.

Composition: Natural Alkaloids and a Synthetic Sedative

The elixir contains four essential active ingredients: the three belladonna alkaloids—Hyoscyamine sulfate, Atropine sulfate, and Scopolamine hydrobromide—and the synthetic compound Phenobarbital. The belladonna alkaloids are derived from natural sources, while Phenobarbital belongs to the barbiturate family.

This specific liquid formulation is a key differentiating factor, as it utilizes a fixed-ratio combination, ensuring consistency across the four components. The medication’s primary classification as an antispasmodic agent is based on the actions of the belladonna alkaloids. The liquid form also facilitates administration, particularly for patients who have difficulty swallowing solid dosage forms.

What is the General Purpose of This Combination?

The general purpose of the formulation is to offer symptomatic relief through an integrated mechanism of effect. The antispasmodic action of the belladonna alkaloids helps mitigate painful muscle contractions and gastrointestinal spasms by directly relaxing the smooth muscles of the gut. Concurrently, the Phenobarbital component provides mild sedation by acting as a CNS depressant. This comprehensive approach is designed to alleviate both the physical symptoms of an overactive gut and the nervous tension that often accompanies and exacerbates digestive discomfort.

What side effects are possible with Donnatal Elixir?

Possible side effects and safety information

The safety profile for Donnatal Elixir is characterized by effects stemming from its combination of anticholinergic alkaloids and the barbiturate, Phenobarbital. The adverse reactions officially documented in regulatory labeling fall across multiple physiological systems.

Adverse Reaction Categories

Side effects are primarily grouped by System-Organ Class (SOC) in official prescribing information:

  • Gastrointestinal Disorders: Commonly include dry mouth (xerostomia), constipation, a bloated feeling, nausea, and vomiting.
  • Nervous System Disorders: Reactions include drowsiness, dizziness, weakness, and nervousness. Paradoxical excitement or agitation may also occur.
  • Ocular & Cardiovascular: Officially listed effects include blurred vision, mydriasis (pupil dilation), and cardiovascular events like tachycardia (fast heart rate) and palpitation.
  • Genitourinary & Skin: Potential effects are urinary hesitancy and retention and decreased sweating (anhidrosis).

Serious Safety Considerations

The regulatory profile documents the risk of severe allergic reactions and drug idiosyncrasies, including anaphylaxis. The phenobarbital component is associated with rare, potentially fatal exfoliative dermatitis (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis).

Duration and Population-Specific Notes

The phenobarbital component may be habit forming, and abrupt cessation in habituated individuals can lead to severe withdrawal symptoms (e.g., delirium or convulsions). The label specifically notes that older adults may react to even small doses with symptoms of excitement, agitation, or increased drowsiness. Due to the anticholinergic action, there is a risk of heat prostration (fever and heatstroke) in high environmental temperatures resulting from reduced ability to sweat.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile outlines documented overdose manifestations stemming from the combination of belladonna alkaloids and the barbiturate sedative. Overdosage may present with a cluster of anticholinergic symptoms, including blurred vision, dilated pupils, dryness of the mouth, hot and dry skin, and difficulty in swallowing. Additional documented signs and symptoms may involve systemic and central nervous system effects such as headache, dizziness, nausea, vomiting, and CNS stimulation.

In the event of suspected overdosage, the clear regulatory instruction is to contact a poison control center or emergency room at once. Immediate emergency medical attention is required to manage these manifestations.

The prescribing information mandates that management consists of specific supportive and procedural measures. These interventions include gastric lavage (stomach wash), the use of emetics to induce vomiting, and the administration of activated charcoal. A theoretical risk of a curare-like action is noted with significant overdosage. Furthermore, elderly patients should be monitored closely, as they may exhibit heightened sensitivity, presenting with signs of excitement, agitation, or drowsiness even at lower exposure levels.

Therapeutic Uses of Donnatal Elixir

What Donnatal Elixir is Used For: Main Therapeutic Applications

Donnatal Elixir is commonly used as adjunctive therapy for managing symptom clusters that may become intense or disruptive, associated with certain gastrointestinal conditions. This combination is considered relevant across conditions involving episodic or fluctuating manifestations that present with symptoms related to physical discomfort and symptoms of increased neurological or muscular activity in the digestive tract.

The formulation is commonly used to help with symptoms in conditions presenting with acute episodes, such as Irritable Bowel Syndrome (IBS) (including what is described as irritable colon, spastic colon, or mucous colitis) and duodenal ulcer.

The overall effect contributes to improved comfort during periods of heightened symptoms, which may assist with easing the overall symptom burden when symptoms become temporarily overwhelming. This supportive relief supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

“The elixir is commonly used during phases when symptoms become more noticeable, where short-term symptomatic assistance is appropriate.”

Quick Fact: Assists with managing Symptoms related to physical discomfort and heightened physiological activity.

Regulatory References

  1. FDA Drug Label for Donnatal

Eligibility and Restrictions for Use

Who Can and Cannot Use Donnatal Elixir?

Eligibility for Donnatal Elixir is strictly defined by regulatory documents, which list absolute prohibitions (contraindications) and populations requiring formal caution. The medicine is primarily intended for adults and certain pediatric patients requiring adjunctive therapy for functional gastrointestinal symptoms.

Absolute Contraindications

Donnatal Elixir is contraindicated and must not be used by patients with specific pre-existing conditions, primarily due to the anticholinergic and barbiturate components. Prohibitions include:

  • Glaucoma or Obstructive Uropathy.
  • Obstructive Disease of the GI Tract (e.g., paralytic ileus, pyloroduodenal stenosis).
  • Severe Ulcerative Colitis or Toxic Megacolon.
  • Acute Intermittent Porphyria or known Hypersensitivity to any ingredient.

Restricted Use and Special Populations

Use requires caution and close oversight for patients with specific health issues or status. This conditional use applies to:

  • Cardiovascular Conditions: Including coronary heart disease, cardiac arrhythmias, or tachycardia.
  • Organ Impairment: Patients with hepatic disease or renal disease.
  • Age: Geriatric (Older Adult) patients are advised caution due to the risk of paradoxical reactions.
  • Pregnancy and Lactation: The drug is formally noted to cause fetal harm and should be used only if clearly needed during pregnancy. Caution is also advised for nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Anticoagulants

Donnatal Elixir contains phenobarbital, a barbiturate component that is known to affect the activity of certain blood-thinning medicines, such as oral anticoagulants. Phenobarbital is a known enzyme inducer, meaning it can increase the rate at which the liver metabolizes, or breaks down, other medicines. This acceleration of metabolism can lead to a decrease in the concentration and therapeutic effect of the concurrently administered anticoagulant.

Interacting Medicine Class Mechanism of Interaction Required Management (Official Statement)
Anticoagulants (e.g., Warfarin) Phenobarbital may decrease the effect of the anticoagulant. Larger doses of the anticoagulant may be needed for optimal effect while taking Donnatal Elixir.

Consequences of Starting and Stopping

If Donnatal Elixir is started in a patient taking an anticoagulant, the dose of the anticoagulant may need to be increased to maintain its proper effect. Conversely, when phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased. Close monitoring of blood clotting indicators is therefore necessary when starting or stopping Donnatal Elixir while on an anticoagulant. Always consult a healthcare provider for any dosage adjustments to avoid serious complications.

Mechanism of Action

Donnatal Elixir functions through the combined actions of its belladonna alkaloids (hyoscyamine, atropine, scopolamine) and phenobarbital, targeting both peripheral autonomic pathways and the central nervous system.

Peripheral Muscarinic Receptor Blockade

The belladonna alkaloids act as competitive antagonists at muscarinic acetylcholine receptors (mAChRs) throughout the peripheral nervous system. By blocking the effect of acetylcholine, the drug suppresses parasympathetic activity, resulting in smooth muscle relaxation in the gastrointestinal and urinary tracts. This modulation restricts the propagation of excessive mediator activity and contributes to pathway stabilization.

Central GABA A Receptor Modulation

Phenobarbital, a long-acting barbiturate, is an allosteric modulator of the GABA A receptor complex. This interaction enhances the inhibitory effects of the neurotransmitter GABA by increasing the duration that chloride channels remain open, promoting neuronal hyperpolarization and general central nervous system (CNS) depression, which modulates subsequent physiological signaling.

Reduced Glandular Secretion

The anticholinergic effect of the alkaloids also extends to exocrine glands, where blocking muscarinic receptors reduces the signaling sequences for secretion. This mechanistic cascade results in a reduction of various bodily secretions, including saliva, sweat, and gastric juices, which influences the resulting physiological state by modifying secretory output.

Dosage and Administration Information

How to Use Donnatal Elixir

Donnatal Elixir is a prescription medication administered exclusively via the oral route. The instructions for its use are structured around achieving symptomatic control through an individualized, multi-dose regimen.

Administration and Dosing Principles

Usage Entity Instruction/Pattern
Administration Route Oral, using the elixir (liquid) form.
Standard Adult Dose 1 to 2 teaspoonfuls (5 mL to 10 mL) per dose.
Dosing Frequency (Adults) Three or four times a day (TID-QID).
Dose Adjustment The dosage must be individually adjusted to the specific needs of the patient to assure symptomatic control.

Population-Specific Use

Administration for specific patient populations varies by group:

  • Pediatric Dosing: Dosage is determined based on the child's body weight and is typically administered at more frequent intervals, such as every 4 to 6 hours. The dose must be measured precisely using a calibrated oral syringe or pediatric dosing device to ensure accuracy.
  • Hepatic Impairment: Caution is advised in patients with liver dysfunction, and the initial doses should be small due to the metabolic pathways of the component drugs.
  • Older Adults: Similar to hepatic impairment, older adults are often managed with smaller initial doses, as they may exhibit increased sensitivity to the effects of the components.

This protocol establishes a standardized, multi-dose oral framework designed to be tailored by the prescriber, focusing solely on the delivery pattern and dose volume necessary for prescribed use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Donnatal Elixir

Evidence for Use in Irritable Bowel Syndrome (IBS)

The evidence base for Donnatal Elixir’s use as adjunctive therapy in conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome (IBS), primarily consists of older Randomized Controlled Trials (RCTs) and small observational studies. These studies were used in research exploring how symptoms change over time in patients taking the combination drug for short-term symptoms of IBS. Research examined short-term outcomes related to physical discomfort, including measurements of abdominal pain, cramping, and changes in bowel habits.

Studies report how symptoms evolved in the observed populations. However, a detailed regulatory review determined that the available evidence was inadequate to establish substantial evidence of effectiveness when measured against modern clinical standards. The official regulatory classification of "Possibly Effective" for this adjunctive use highlights what is known — and what is still uncertain—about the evidence base for consistent results. Evidence quality varies across studies, and existing research provides limited insight into outcomes over extended periods.

Evidence for Use as Adjunctive Therapy for Duodenal Ulcer

Research into the adjunctive use of this combination drug for duodenal ulcer relies on older clinical research that was later evaluated through comprehensive Regulatory Reviews. Research examined outcomes related to systemic or functional imbalance, such as duodenal ulcer healing rates, recurrence, and complication prevention. The regulatory review concluded that the available data did not conclusively show whether the observed changes were attributable to the combination in the study settings. The regulatory review noted that the evidence did not conclusively show that the combination was associated with changes in ulcer healing or complication prevention.

There is limited information for long-term outcomes, particularly concerning whether the combination may affect the rate of ulcer recurrence. The classification of "Possibly Effective" highlights that substantial evidence of efficacy for this adjunctive use is limited.

Long-Term Studies and Follow-Up Data

Studies conducted during periods of increased symptom activity typically focused on short-term relief. While some older research included observations extending up to the intermediate term, these studies were later deemed inadequate to definitively establish long-term effectiveness. Therefore, the long-term effects are not fully established, particularly concerning whether the combination may affect the long-term course of conditions presenting with cycles of stability and flare-ups.

What Regulatory Reviews Indicate About Evidence Strength

The most significant finding from the official Regulatory Reviews is that the overall evidence supporting the effectiveness of the combination drug has been officially categorized as "Possibly Effective" for its adjunctive uses. This classification reflects that evidence is limited and does not meet the regulatory standard of substantial evidence of effectiveness required for definitive claims. Research provides context but not individual predictions, highlighting that the evidence is generally contributing to understanding symptom patterns but does not determine whether an individual will respond similarly.

Key Studies & References FDA Drug Label for Donnatal (Belladonna Alkaloids and Phenobarbital Elixir) – Indication and Regulatory Status

Frequently Asked Questions (FAQ)

Common questions about Donnatal Elixir (FAQ)

Q: Will this medicine affect my ability to drive?

Official product information for this medicine states that it may cause side effects such as dizziness, sleepiness, and blurred vision. These effects can impair coordination. Because of this, patients are generally advised to avoid driving or operating complex machinery until they know how Donnatal Elixir affects them, as indicated on the official labeling.

Q: What should I do if I miss a dose?

According to the official drug label, if a dose is missed by only a few hours, it may be taken as soon as remembered. However, if it is close to the time for the next scheduled dose, the official product information advises skipping the missed dose and resuming the regular dosing schedule. Do not take two doses at the same time to make up for a missed dose, as per the label instructions.

How should Donnatal Elixir be stored and disposed of?

Official Storage Requirements

Donnatal Elixir must be stored strictly according to the conditions defined in the official drug labeling to preserve the stability of the pharmaceutical solution.

Condition Requirement
Temperature Store at USP Controlled Room Temperature (20 C to 25 C or 68 F to 77 F).
Prohibited The product must AVOID FREEZING.
Protection Keep protected from light and moisture in a tight, light-resistant container.
Child Safety Due to the presence of Phenobarbital, the elixir must be stored out of the sight and reach of children using a child-resistant closure.

Official Disposal Instructions

Unused or expired elixir must be disposed of safely. The official guidance recommends taking the medicine to a drug take-back location. If a take-back program is unavailable, the product may be discarded in the household trash after mixing it with an unappealing substance like dirt or coffee grounds and sealing it in a plastic bag. This product is not on the FDA's flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Donnatal Elixir found in:

A-Z Index: